Abstract Number: 0237 • ACR Convergence 2021
Self-perceived General Health at Start of Anti-TNF Therapy Predicts Therapeutic Response in Patients with Rheumatoid Arthritis: Analysis from the Czech Biologics Registry ATTRA
Background/Purpose: SF-36 and its components, as well as other PROs have been shown to predict various disease outcomes. We hypothesized that positive responses to questions…Abstract Number: 0844 • ACR Convergence 2021
Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) experience refractory disease and do not attain remission imparting worse long-term outcomes. We evaluated RA patients…Abstract Number: 0245 • ACR Convergence 2021
Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry
Background/Purpose: Abatacept (ABA) is well tolerated and effective in patients with JIA.1 The Pediatric Rheumatology Collaborative Study Group (PRCSG)/ Paediatric Rheumatology INternational Trials Organisation (PRINTO)…Abstract Number: 0853 • ACR Convergence 2021
A Combined Patient Registry and Biobank Laboratory Information System for Prospective Multisite Chronic Rheumatic Disease Research Using REDCap
Background/Purpose: As we enter the big data revolution, comprehensive informatics solutions are essential to realising precision medicine for rheumatic and other chronic disease patients, especially…Abstract Number: 0254 • ACR Convergence 2021
Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis
Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…Abstract Number: 0933 • ACR Convergence 2021
Sustained Functional Remission in Axial Spondyloarthritis (axSpA): Which Are the Primary Outcomes That Should Be Targeted to Achieve This?
Background/Purpose: A treat-to-target (T2T) strategy has been advocated for the management of axSpA although no consensus exists as to the most appropriate target or the…Abstract Number: 0255 • ACR Convergence 2021
Identification of Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: Recent treat to target recommendations for the treatment of juvenile idiopathic arthritis (JIA) recommend frequent evaluation and treatment intensification until the disease activity target…Abstract Number: 1217 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease-…Abstract Number: 0336 • ACR Convergence 2021
The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE
Background/Purpose: The comparative clinical utility of various diagnostic tests to aid the differential diagnosis of SLE is unclear. We compare the outcomes of testing with…Abstract Number: 1264 • ACR Convergence 2021
Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study
Background/Purpose: Black patients with systemic lupus erythematosus (SLE) face higher rates of morbidity and mortality compared to White patients. Long-term glucocorticoid use has been associated…Abstract Number: 0354 • ACR Convergence 2021
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…Abstract Number: 1364 • ACR Convergence 2021
Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment
Background/Purpose: Autologous hematopoietic stem cell transplantation (AHSCT) is now established as a preferred standard of care treatment for patients with severe scleroderma with internal organ…Abstract Number: 0372 • ACR Convergence 2021
Impact of Gender and Age on Ankylosing Spondylitis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
Background/Purpose: Gender and age have been previously identified as independent predictors of response to anti-TNFs. The aim of this analysis was to compare, between genders…Abstract Number: 1442 • ACR Convergence 2021
Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
Background/Purpose: With the arrival of new Janus kinase inhibitors (JAKi), with different JAK inhibition profiles, there is the possibility of using a second JAKi in…Abstract Number: 0183 • ACR Convergence 2020
Incidence of Malignancies in Japanese Patients with Rheumatoid Arthritis: Data from a Large Japanese National Registry
Background/Purpose: Patients (pts) with RA have an increased risk of some malignancies compared with the general population, and this can vary by region/race.1,2 Epidemiologic data…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 18
- Next Page »